{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-16T01:42:34.166Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"ARQT\",\n \"company\": \"Arcutis Biotherapeutics, Inc.\",\n \"investigation_summary\": \"Arcutis reported strong Q1 2026 net product revenue of $105.4M (+65% YoY) and turned cash-flow positive for the first time in company history ($2.2M operating CF). However, shares dropped ~11% post-earnings on a guidance-related selloff that appears overdone relative to confirmed fundamentals. Seven Form 4 filings in 14 days cluster around May 4 and May 11, with multiple insiders buying open-market at $21-$22 — precisely near the bottom of this drawdown from the 52-week high of $31.77. A pending FDA sNDA for ZORYVE cream expansion to infants as young as 3 months (submitted April 27) represents a named catalyst that could re-rate the stock, and several Wall Street analysts are clustering around $34-35 targets. The stock is below both its 50DMA and 200DMA with RSI in neutral territory (~41), consistent with accumulation rather than distribution.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 4,\n \"structure_hints\": [\n \"cc\",\n \"strangle\"\n ],\n \"business_snapshot\": \"Arcutis Biotherapeutics is a commercial-stage dermatology biotech whose only product, ZORYVE (topical roflumilast cream 0.3%, foam for seborrheic dermatitis, and cream 0.15%/0.05% for psoriasis and atopic dermatitis), generated $415M in TTM revenue with 60% YoY growth. The company achieved its first operating cash flow positive quarter (Q1 2026: +$2.24M) while reaffirming full-year 2026 net product revenue guidance of $480-$495M — implying ~$190-205M in Q2-Q4 combined, a significant ramp. Gross margins are approximately 91%, among the best in specialty pharma. The balance sheet shows $224M cash + $189M marketable securities against $115M total debt ($7.95M current portion). Key pipeline: ZORYVE cream sNDA for infants ages 3+ months with atopic dermatitis pending FDA review; ARQ-234 early-stage CD200R agonist asset in development.\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [],\n \"insider_open_market_total_usd_90d\": 0,\n \"distinct_insider_buyers_90d\": 0,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": false,\n \"material_insider_selling_90d_usd\": 0,\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-08-05\",\n \"recent_eps_surprise_pattern\": \"Beat revenue (+6.3%) but missed EPS (-55% vs est) in Q1 2026; prior three quarters: +164% (Q3 2025), +47% (Q4 2025), +18% (Q2 2025). Pattern suggests transient guidance-selloff, not structural miss.\",\n \"guidance_raise_in_last_90d\": false,\n \"named_catalysts\": [\n {\n \"type\": \"regulatory\",\n \"description\": \"FDA sNDA submitted April 27, 2026 for ZORYVE cream 0.05% expansion to infants ages 3-24 months with mild-to-moderate atopic dermatitis — addressable population ~1 million U.S. children under age 2; PDUFA date not yet set but approval would be a major label expansion event\",\n \"date_or_window\": \"FDA decision expected H2 2026\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-submits-supplemental-drug-application-120000919.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"product\",\n \"description\": \"AAD (American Academy of Dermatology) issued first-ever pediatric AD guidelines with STRONG recommendation for ZORYVE cream as steroid-free option — clinical validation that could drive formulary inclusion and payer coverage expansion\",\n \"date_or_window\": \"April 22, 2026\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-zoryve-roflumilast-cream-receives-120000398.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"guidance\",\n \"description\": \"Q1 beat + reaffirmed FY2026 $480-$495M net product revenue guidance — implies Q2-Q4 must deliver ~$187.5M/qtr vs Q1's $105.4M, a significant ramp; execution on this ramp is the next major re-rating catalyst\",\n \"date_or_window\": \"May 6, 2026 earnings release\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-announces-first-quarter-2026-200000402.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"earnings\",\n \"description\": \"Q2 2026 results — first look at revenue ramp trajectory; FY guidance confirmation or revision will drive next major re-rating\",\n \"date_or_window\": \"August 5, 2026\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/earnings\"\n ],\n \"directional_bias\": \"ambiguous\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": 18.45,\n \"sector_median_forward_pe\": null,\n \"ev_to_ebitda\": 468.14,\n \"sector_median_ev_to_ebitda\": null,\n \"fcf_yield_pct\": 0.13,\n \"narrative\": \"Forward P/E of 18.4x is reasonable for a dermatology growth story with 60% revenue CAGR and path to profitability — especially vs. specialty pharma/biotech peers trading at 25-35x. The stock has pulled back ~33% from its 52-week high ($31.77) on what appears to be a Q1 guidance-selloff rather than fundamental deterioration, creating an entry opportunity ahead of the ZORYVE infant expansion approval decision.\"\n },\n \"quality\": {\n \"roic_pct\": null,\n \"gross_margin_trend_pp_yoy\": null,\n \"net_debt_to_ebitda\": null,\n \"balance_sheet_grade\": \"B+\"\n },\n \"technical\": {\n \"above_50dma\": false,\n \"above_200dma\": false,\n \"rsi_14\": 41.4,\n \"macd_recent_bullish_cross\": false,\n \"12_1_momentum_vs_sector_pct\": null\n }\n },\n \"price_context\": {\n \"last_close\": 21.32,\n \"ytd_return_pct\": -19.8,\n \"from_52w_high_pct\": -32.9\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-Q\",\n \"filed\": \"2026-05-06\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000040/arqt-20260331.htm\",\n \"key_takeaways\": [\n \"Q1 2026 net product revenue $105.4M (+65% YoY) — beat consensus +6.3%; company turned cash-flow positive for first time ever ($2.24M operating CF); reaffirmed FY2026 guidance of $480-$495M; gross margin ~90.7%; inventory build ($22.6M to $37.4M) ahead of revenue ramp; R&D spend increased 75% YoY to $30.6M as pipeline investment accelerates\",\n \"Accrued and other current liabilities surged from $116.3M to $137M — primarily rebates/chargebacks accruals consistent with higher gross-to-net adjustments at scale\",\n \"Cash + marketable securities = ~$224M; total debt $109M (current portion $7.95M maturing June 2026 for Tranche C2)\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-05-06\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000039/arqt-20260506.htm\",\n \"key_takeaways\": [\n \"Earnings press release filing — confirmed Q1 results and business update\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-06-18\",\n \"2026-09-18\"\n ],\n \"iv_summary\": \"ATM IV approximately 60-67% across near-term expiries; OTM calls at +10-15% strikes show elevated but not extreme premium. The 30-delta call OI cluster at $30 (883 contracts) suggests traders are positioning for upside, while put OI at $20 ($22.5 strike = 300/76 respectively) shows solid support.\",\n \"notable_skew_or_flow\": \"Put/call ratio of 0.94 is nearly balanced; net dollar flow slightly bearish (-$5.4K). No whale blocks detected on crude feed. High open interest in $30 calls (883) and $20 puts (300) suggests the market sees this range-bound between ~$18-$30 for now. IV elevated enough to make covered call writing attractive at these levels.\"\n },\n \"competitive_landscape\": \"Arcutis competes primarily against Incyte's OPZELURA (ruxolitinib cream, $1.6B+ peak potential) in AD/topical PDE4/JAK space; ZORYVE differentiates as a once-daily steroid-free roflumilast formulation with superior tolerability profile vs. JAK inhibitors which carry black box warnings. Key competitors: Pfizer (Crisaborole/Eucrisa — genericized), LEO Pharma (trilaciclib in pipeline), others targeting the ~$8B U.S. topical dermatology market for inflammatory conditions.\",\n \"key_risks\": [\n \"Revenue concentration risk: single product franchise ZORYVE across multiple indications makes any competitive setback highly impactful\",\n \"Gross-to-net headwinds: high rebates/chargebacks (reflected in ballooning accrued liabilities) could pressure effective price realization even as gross revenue grows\",\n \"FDA sNDA approval for infant expansion not guaranteed — FDA may require additional data or impose label restrictions; PDUFA date uncertainty adds timing risk\",\n \"Near-term debt maturity: Tranche C2 ($7.95M current portion) due June 2026 requires refinancing if operating cash flow doesn't fully cover — manageable given ~$224M cash but worth monitoring\",\n \"High R&D spend (75% YoY increase in Q1) and SG&A expansion as company scales could delay path to sustained profitability beyond Q1's one-time positive print\"\n ],\n \"what_the_market_might_be_missing\": \"The May 2026 insider cluster buying open-market at ~$21-$22 post-Q1 selloff is a high-conviction signal — insiders have precise visibility into Q2 prescription trends, rebate dynamics with payers (which are driving the accrued liability build), and whether FY guidance of $480-495M remains on track. Multiple insiders from distinct roles buying simultaneously over two dates (May 4, May 11) in the same narrow window suggests coordinated conviction rather than individual random timing. Combined with ZORYVE's inclusion as a Strong Recommendation in AAD's first-ever pediatric AD guidelines and analyst targets clustering at $34-35 (implying ~60% upside from current levels), the stock appears positioned for a re-rating once Q2 revenue ramp is confirmed at August earnings.\",\n \"anti_signals\": [\n \"concentration\",\n \"dilution\"\n ],\n \"sources\": [\n {\n \"label\": \"Q1 2026 earnings press release / 8-K\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-announces-first-quarter-2026-200000402.html\"\n },\n {\n \"label\": \"sNDA submission for ZORYVE infant expansion\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-submits-supplemental-drug-application-120000919.html\"\n },\n {\n \"label\": \"AAD pediatric AD guidelines recommendation\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-zoryve-roflumilast-cream-receives-120000398.html\"\n },\n {\n \"label\": \"Analyst $35 price target narrative\",\n \"url\": \"https://finance.yahoo.com/markets/stocks/articles/arcutis-biotherapeutics-arqt-narrative-shifting-180534425.html\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-16T01:43:15.199Z", "raw_content": "The dossier is for ARQT (Arcutis Biotherapeutics, Inc.).\nScout verdict: range_bound_or_income.\nStructure hints: cc, strangle.\nMarket cap: Not explicitly given, but last close $21.32. I'll assume it's small-cap or micro-cap (<$5B), but the prompt says \"risk_class — choose one based on market_cap field\". It's not in the dossier, but biotechs with ~$1B revenue and $21 share price are usually mid/small cap. I'll classify as \"asymmetric\" or \"core\" depending on typical size, but let's stick to the rubric. Actually, I can just pick based on the prompt's instruction: \"market_cap ≤ $5B\" -> asymmetric. I'll assume it's asymmetric given the biotech nature, or I can just pick \"core\" if it's >$5B. Wait, $21 * ~100M shares = $2.1B. So asymmetric.\nLet's score it.\n\nA. SMART-MONEY CLUSTER: 0 pts. (insider_open_market_purchases_90d is empty in scoring_inputs, though investigation_summary mentions it. I must use scoring_inputs. It says 0. So 0.)\nB. OPTIONS FLOW / UOA: 0 pts. (No whale blocks, balanced P/C ratio, IV elevated but no specific UOA signal matching criteria. IV is 60-67%, which is high, but no specific pts triggered.)\nC. CATALYST: 5 pts. (Pending product launch / FDA / contract milestone: sNDA for ZORYVE infant expansion. Date: H2 2026. Maybe 8 pts? The rubric says 8 pts for pending product launch / FDA / contract milestone in horizon. I'll give 8 pts.)\nD. MISPRICING: 0 pts. (Forward P/E 18.45, not ≥20% below sector median. EV/EBITDA 468. FCF yield 0.13%. No SOTP gap.)\nE. QUALITY: 0 pts. (ROIC null, gross margin trend null, net debt/EBITDA null. Balance sheet B+ but rubric asks for specific metrics.)\nF. MOMENTUM/TECHNICAL: 0 pts. (Below 50DMA and 200DMA. RSI 41.4. No momentum.)\n\nTotal Score: ~13.\nRisk Class: asymmetric.\nThresholds for asymmetric: <60 Skip.\nAnti-signals: concentration, dilution. The dossier mentions \"Revenue concentration risk: single product franchise ZORYVE\" and \"dilution\" in anti_signals. This triggers the gate.\nEdge check: \"The market might be missing insider buying and FDA catalyst.\" But scoring inputs show 0 insider buys. The dossier contradicts itself slightly, but I must rely on scoring_inputs for the rubric. Even if I gave it points, it's well below 60.\nVerdict: range_bound_or_income. The dossier explicitly flags anti_signals for concentration and dilution.\nI will skip.\n\nReason: Dossier flags material anti-signals (single-product revenue concentration and potential dilution overhang) and lacks the quantitative catalysts, smart-money cluster, or technical momentum required to clear the scoring threshold; the elevated IV does not compensate for the asymmetric risk profile of a commercial-stage biotech with a binary FDA event and no structural earnings tailwind.\n\nWait, let's double check scoring_inputs for catalyst. It has named_catalysts with FDA sNDA and AAD guidelines. I'll give it 8 pts for catalyst.\nScore breakdown: smart_money: 0, options_flow: 0, catalyst: 8, mispricing: 0, quality: 0, technical: 0. Total: 8.\nThis is a clear skip.\n\nI will format the output exactly as requested.\nCheck structure:\n{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0, \"options_flow\": 0, \"catalyst\": 8,\n \"mispricing\": 0, \"quality\": 0, \"technical\": 0\n },\n \"reason\": \"Dossier flags material anti-signals (single-product revenue concentration and dilution overhang) and lacks the quantitative catalysts, smart-money cluster, or technical momentum required to clear the scoring threshold; the elevated IV does not compensate for the asymmetric risk profile of a commercial-stage biotech with a binary FDA event and no structural earnings tailwind.\"\n}\nAll numbers match. I'll output this.\nOne minor thing: The prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" The dossier has \"anti_signals\": [\"concentration\", \"dilution\"]. I will mention that.\nReady.✅\nOutput matches requirements. No markdown fences. Valid JSON.\nProceed. \nSelf-Correction/Refinement during thought: \nWait, the prompt says \"If scoring_inputs has anti_signals_present non-empty...\". The dossier has a top-level \"anti_signals\" array, not inside scoring_inputs. But it's clearly present. I'll stick with skip.\nScore is very low. I will just output the JSON.\nAll good. \nOutput matches exactly. \nProceeds. \n[Output Generation] -> JSON string. \nCheck schema for skip: exactly as requested.\nDone. \nOutput Generation. \n```json\n{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 8,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"Dossier flags material anti-signals (single-product revenue concentration and dilution overhang) and lacks the quantitative catalysts, smart-money cluster, or technical momentum required to clear the scoring threshold; the elevated IV does not compensate for the asymmetric risk profile of a commercial-stage biotech with a binary FDA event and no structural earnings tailwind.\"\n}\n```\nWait, the prompt says \"Output ONLY the decision JSON described in the system prompt. Do NOT include reasoning blocks\". I will output raw JSON.\nAll good. \nProceeds. \n(Self-Correction/Verification during generation prep)\nLet's verify the score breakdown matches the rubric exactly.\nA: 0\nB: 0\nC: 8 (pending FDA sNDA)\nD: 0\nE: 0\nF: 0\nTotal: 8.\nMatches.\nOutput matches requested format.\nDone. \n[Output Generation] -> *Proceeds*\n\n\n{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 8,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"Dossier flags material anti-signals (single-product revenue concentration and dilution overhang) and lacks the quantitative catalysts, smart-money cluster, or technical momentum required to clear the scoring threshold; the elevated IV does not compensate for the asymmetric risk profile of a commercial-stage biotech with a binary FDA event and no structural earnings tailwind.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 8,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"Dossier flags material anti-signals (single-product revenue concentration and dilution overhang) and lacks the quantitative catalysts, smart-money cluster, or technical momentum required to clear the scoring threshold; the elevated IV does not compensate for the asymmetric risk profile of a commercial-stage biotech with a binary FDA event and no structural earnings tailwind.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 8,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"Dossier flags material anti-signals (single-product revenue concentration and dilution overhang) and lacks the quantitative catalysts, smart-money cluster, or technical momentum required to clear the scoring threshold; the elevated IV does not compensate for the asymmetric risk profile of a commercial-stage biotech with a binary FDA event and no structural earnings tailwind.\"\n}", "tool_calls_total": 0, "walltime_ms": 41034, "stop_reason": "stop", "completed_at": "2026-05-16T01:43:15.200Z" }